AZN Analysis & News - AstraZeneca Group plc | Seeking Alpha

AZN

AstraZeneca Group plc | NYSE

1d 5d 1m 6m 1y 5y 10Y Advanced Chart

52wk high:37.30

52wk low:28.43

EPS:1.12

PE (ttm):33.02

Div Rate (ttm):1.90

Yield (ttm):5.13%

Market Cap:$93.83B

Volume:

Analysis

AstraZeneca Sees A Phase 3 Flop, But Not All Is Lost
Terry Chrisomalis•Mon, May 14•2 Comments
How Will This Unexpected War For First-Line Lung End?
Zach Hartman•Mon, Apr. 16•14 Comments
AstraZeneca Looks To Prove Itself In The Type 2 Diabetes Market
Terry Chrisomalis•Thu, Mar. 22•10 Comments
I've Sold AstraZeneca Because Of Its Rising Share Price And Weak Results
John Kingham•Fri, Mar. 9•20 Comments
AstraZeneca Scores FDA First, Time To Capitalize Before Competitors Roll In
Terry Chrisomalis•Mon, Feb. 19•7 Comments
Biotech Analysis Central Pharma News: Galectin's Failure, Revance's Positive Results, Novo Nordisk's FDA Win
Terry Chrisomalis•Dec. 6, 2017•28 Comments
Your Daily Pharma Scoop: Portola Ahead Of Catalysts, AstraZeneca Gets 2 FDA Approvals, GW Pharmaceuticals' Price Target Lowered
Avisol Capital Partners•Nov. 15, 2017•3 Comments
Your Daily Pharma Scoop: AstraZeneca's Imfinzi SBLA; Ablynx U.S. IPO; Is Teva A Buy?
Avisol Capital Partners•Oct. 18, 2017•6 Comments
Exploring AstraZeneca's Two-Pronged Assault On Lung Cancer
Zach Hartman•Oct. 18, 2017•9 Comments
Your Daily Pharma Scoop: MannKind Is A Trade Not An Investment; AstraZeneca's Imfinzi
Avisol Capital Partners•Oct. 10, 2017•84 Comments
AstraZeneca: Is It Investable After Imfinzi Failure?
Avisol Capital Partners•Sep. 8, 2017•21 Comments
AstraZeneca: Tremendous Upside Potential
Elderberry Investments•Aug. 22, 2017•2 Comments
AstraZeneca, Time To Expand The Operation
Terry Chrisomalis•Aug. 18, 2017•3 Comments
After AstraZeneca's 'Disaster', What's In Store For Their Immune Checkpoint Program?
Zach Hartman•Aug. 3, 2017•16 Comments
AstraZeneca Stages Major Lung Cancer Comeback
Terry Chrisomalis•Aug. 2, 2017•2 Comments

News

AstraZeneca's Imfinzi successful in late-state lung cancer study
SA News•Fri, May 25•1 Comment
Healthcare roundup
SA News•Fri, May 25•1 Comment
AstraZeneca submits sNDA in Japan for Forxiga in type-1 diabetes
SA News•Mon, May 21
FDA's OKs AstraZeneca's Lokelma for hyperkalemia
SA News•Mon, May 21•1 Comment
AstraZeneca's (AZN) CEO Pascal Soriot on Q1 2018 Results - Earnings Call Transcript
SA Transcripts•Fri, May 18
AstraZeneca Group plc 2018 Q1 - Results - Earnings Call Slides
SA Transcripts•Fri, May 18
J&J bails on Alzheimer's candidate atabecestat on toxicity issues
SA News•Fri, May 18•18 Comments
AstraZeneca Q1 revenues down 4%; shares off 2% premarket
SA News•Fri, May 18•2 Comments
AstraZeneca beats by $0.13, misses on revenue
SA News•Fri, May 18
Notable earnings before Friday’s open
SA News•Thu, May 17•4 Comments
AstraZeneca's benralizumab flunks late-stage COPD study
SA News•Fri, May 11
Expanded use of Lynparza approved in Europe
SA News•Tue, May 8•1 Comment
Developers backing away from IDO inhibitors after Incyte's epacadostat flop
SA News•Tue, May 1•15 Comments
European advisory group April meeting results
SA News•Fri, Apr. 27•6 Comments
Zai Lab in-licenses Entasis Therapeutics' broad-spectrum antibiotic in Asia-Pacific; shares up 3%
SA News•Wed, Apr. 25

Partner News

AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia
at Zacks.com (Mon, 11:09AM)
London Markets: U.K. stocks fall from record as AstraZeneca, mining stocks decline
at MarketWatch.com (May 18, 2018)
AstraZeneca's (AZN) Q1 Earnings & Sales Miss, Stock Down
at Zacks.com (May 18, 2018)
European markets lower amid US-China trade news; Richemont down 5%
at CNBC (May 18, 2018)
Is a Surprise Coming for AstraZeneca (AZN) This Earnings Season?
at Zacks.com (May 17, 2018)
Analysts’ Recommendations for AstraZeneca as of May 15
at MarketRealist.com (May 16, 2018)
AstraZeneca’s 1Q18 Estimates: CVMD Products
at MarketRealist.com (May 16, 2018)
AstraZeneca’s 1Q18 Estimates: Oncology Products
at MarketRealist.com (May 16, 2018)
AstraZeneca’s 1Q18 Estimates: Respiratory Products
at MarketRealist.com (May 15, 2018)
AstraZeneca’s 1Q18 Estimates: Segment-by-Segment Revenues
at MarketRealist.com (May 15, 2018)